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Structure-activityrelationshipstudieswerecarriedoutonmacrocyclichexaoxazole(6OTD)dimers,whosecorestructurestabilizes
telomericG-quadruplexes(G4).Twonew6OTDdimershavingsidechainamineandguanidinefunctionalgroupsweresynthesized
and evaluated for their stabilizing ability against a telomeric G4 DNA sequence. The results show that the 6OTD dimers interact
with the DNA to form 1:1 complexes and stabilize the antiparallel G4 structure of DNA in the presence of potassium cation. The
guanidine functionalized dimer displays a potent stabilizing ability of the G4 structure, as determined by using a FRET melting
assay (ΔTm = 14 ◦C).
1.Introduction
G-quadruplexes (G4), secondary DNA structures consisting
of G-quartet planers in G-rich regions, play signiﬁcant
biological roles for example, control of transcription and
telomeric lengths [1–19]. One typical G4 forming DNA
sequence is a telomere, which exists at the ends of chromo-
somes consisting of (TTAGGG)n repeating single-stranded
sequences [1–12]. Telomeres protect chromosomes from end
to end fusion events, which result in replication of the
chromosome (the Hayﬂick limit) [20] .T h et e l o m e r er e p e a t s
are elongated by the reverse transcriptase telomerase, which
is overexpressed in most tumor cells. In contrast, telomerase
activity is not observed in normal somatic cells [21]. Since
the activity of this enzyme is inhibited by the G4 structure
of telomeres owing to steric hindrance, small molecules
that selectively bind and stabilize the telomeric G4 should
be potential anticancer agents. As a result, a number of
G4 ligands, inspired by artiﬁcial DNA intercalators as well
as natural products, have been developed during the past
decade [22].
Telomestatin (TMS) is a natural product isolated from
Streptomyces anulatus 3533-SV4, which displays one of the
most potent telomeric G4 binding activity (Figure 1)[ 23–
28]. Interaction analysis has shown that two molecules of
TMS induce conversion of telomeric G4 into an antiparallel
type by way of an end stacking mode [25–28]. We have
recently developed macrocyclic hexaoxazole compounds
6OTD, containing a variety of side chain functional groups,
that serve as a novel TMS derivative [29–32]. In addi-
tion, by considering the proposed binding mode of TMS
with telomeric G4, we have carried out further structural
development of dimeric 6OTD derivatives (Figure 1)[ 33].
The results of molecular dynamics calculations guided the
selection of 6OTD dimer 1 that contains an appropriate
length of a linker between the monomeric units of 6OTD.
Studies showed that dimer 1 binds to telomeric G4 more
tightly than do other 6OTD dimers with linkers of shorter or2 Journal of Nucleic Acids
longer lengths. One possible structural development strategy
toenhancethestabilizingabilityof 1againsttheG4wouldbe
to install cationic functional groups on the side chain [30].
Below, we describe synthesis of new 6OTD dimers 2 and 3
that derivatize 1 but possess cationic amine and guanidine
functionalgroupsontheirsidechains.Inaddition,theability
of these substances to stabilize telomeric G4 along with their
interaction mode was investigated.
2.MaterialsandMethods
2.1. General. Flash chromatography was performed on Silica
gel 60 (spherical, particle size 0.040∼0.100μm; Kanto).
Optical rotations were measured on a JASCO P-2200
polarimeter, using the sodium D line. 1Ha n d 13CN M R
spectra were recorded on JEOL JNM-ECX 300, 400, and 500.
The spectra are referenced internally according to residual
solvent signals of CDCl3 ( 1HN M R ;δ = 7.26ppm, 13C
NMR δ = 77.0; ppm) and DMSO d − 6( 1HN M R ; δ =
2.50ppm, 13CN M R ; δ = 39.5ppm). Data for 1HN M Ra r e
recorded as follows: chemical shift (δ, ppm), multiplicity (s,
singlet; d, doublet; m, multiplet; br, broad), integration, and
coupling constant (Hz). Data for 13CN M Ra r er e p o r t e di n
terms of chemical shift (δ, ppm). Mass spectra were recorded
on a JEOL JMS-T100X spectrometer with ESI-MASS mode
using methanol as solvent. All oligonucleotides puriﬁed were
obtained from Sigma Genosys and dissolved in double-
distilled water to be used without further puriﬁcation.
Fluorescenceresonanceenergytransfer(FRET)meltingassay
was made with an excitation wavelength of 470–505nm
and a detection wavelength of 523–543 nm using the
DNA Engine Opticon 2 Real-Time Cycler PCR detection
system (BioRad). CD spectra were recorded on a JASCO-
810 spectropolarimeter (Jasco, Easton, MD) using a quartz
cell of 1mm optical path length and an instrument scanning
speed of 500nm/min with a response time of 1s, and
over a wavelength range of 220–320nm. CD spectra are
representative of ten averaged scans taken at 25
◦C.
2.2. Synthesis
Synthesis of 5. To a solution of trioxazole 4 (2.1g, 3.6mmol)
in MeOH-THF (1:1, 60mL) was added Pd(OH)2/C
(420mg), and the reaction mixture was stirred at room
temperature under hydrogen gas (balloon). After 3h, the
catalyst was removed by ﬁltration through a pad of Celite,
and the ﬁltrates were concentrated in vacuo to give amine 5,
which was used without further puriﬁcation.
Synthesis of 7. To a solution of trioxazole 6 (2.1g, 3.6mmol)
in THF-H2O (3:1, 80mL) was added LiOH (230mg,
5.4mmol) at 0◦C. After stirring at room temperature
for 1h,to the resulting mixture was added 1N HCl, to
give carboxylic acid 7, which was used without further
puriﬁcation.
Synthesis of 8. To a solution of amine5(abovementioned) in
THF-H2O (1:1) was added the carboxylic acid 7 (above-
mentioned), N-methylmorpholine (1.2mL, 11mmol), and
4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-
ium chloride (DMT-MM) (3.0g, 11mmol), and the mixture
was stirred at room temperature for 15h. To the reaction
mixture was added H2O and precipitate was formed. This
precipitate was collected with ﬁltration using ﬁlter paper,
to give 8 as a white solid (3.3g, 3.2mmol 89% 2 steps, mp
= 200–203
◦C). Spectral data for 8:[ α]
25
D = −2.7 (c 1.1,
CHCl3–MeOH (1:1)); 1H NMR (300MHz, CDCl3) δ 8.43
(s, 1H), 8.35–8.27 (m, 5H), 7.53 (d, J = 8.9Hz, 1H), 7.34
(m, 5H), 5.98–5.81 (m, 1H), 5.57–5.44 (m, 2H), 5.30 (d,
J = 18Hz, 1H), 5.21 (d, J = 11Hz, 1H), 5.15–4.97 (m,
2H), 4.82 (br, 1H), 4.58 (d, J = 5.5 Hz, 3H), 3.95 (s, 3H),
3.30–3.01 (m, 4H), 2.25–1.80 (m, 4H), 1.70–1.30 (m, 17H);
13C NMR (125MHz, DMSO d − 6) δ 165.7, 165.2, 160.9,
159.8, 156.1, 155.8, 155.7, 155.6, 155.0, 154.4, 145.7, 142.8,
141.0, 140.9, 140.7, 137.3, 136.6, 133.4, 133.3, 130.1, 130.0,
128.9, 128.8, 128.3, 127.7, 117.3, 77.3, 65.1, 64.9, 64.7, 52.0,
48.9, 46.8, 31.8, 31.3, 29.2, 28.9, 28.2, 28.1, 22.8, 22.6; HRMS
(ESI, M + Na) calcd for C48H52N10O15Na 1031.3511, found
1031.3479.
Synthesis of 9. T oas o l u t i o no fb i s - t r i o x a z o l e8 (510mg,
0.50mmol) in DMF-THF (1 : 5, 30mL) was added morpho-
line(440μL,5.0mmol)andPd(PPh3)4 (29mg,0.025mmol),
and the mixture was stirred at room temperature for 1h. To
the reaction mixture was added ether and precipitate was
formed. This precipitate was collected with ﬁltration using
ﬁlter paper. The solid was puriﬁed by column chromatogra-
phy on silica gel (CHCl3-MeOH = 9:1 )t og i v e9 (460mg,
0.50mmol 99%). Spectral data for 9:[ α]
25
D = 28 (c 1.0,
CHCl3-MeOH (1 : 1)); 1H NMR (300MHz, CDCl3) δ 8.43
( s ,1 H ) ,8 . 3 5 – 8 . 2 5( m ,5 H ) ,7 . 5 3( d ,J = 8.9Hz, 1H), 7.33 (m,
5 H ) ,5 . 5 6 – 5 . 4 3( m ,1 H ) ,5 . 0 8( b r ,2 H ) ,4 . 8 0( b r ,1 H ) ,4 . 5 6
(br, 1H), 4.14–4.05 (m, 1H), 3.95 (s, 3H), 3.26–3.04 (m, 4H),
2.25–1.75(m,4H),1.73–1.30(m,17H); 13CNMR(125MHz,
DMSO d − 6) δ 169.3, 165.2, 160.9, 159.8, 156.1, 155.9,
155.7, 155.6, 154.9, 154.4, 145.7, 142.7, 141.0, 140.9, 140.6,
140.5, 137.3, 136.6, 133.3, 130.0, 129.9, 128.8, 128.5, 128.3,
127.7, 77.3, 65.1, 52.0, 49.4, 46.7, 35.3, 31.3, 29.2, 28.2, 28.1,
22.8, 22.6; HRMS (ESI, M + Na) calcd for C44H48N10O13Na
947.3300, found 947.3308.
Synthesis of 10. To a solution of bis-trioxazole 9 (2.2g,
2.4mmol) in THF-H2O (3 : 1, 200mL) was added lithium
hydroxide (300mg, 7.2mmol), and the mixture was stirred
at room temperature for 2h. To the reaction mixture was
added 1N HCl, and the resulting mixture was concentrated
in vacuo. To the residual solution in DMF-CH2Cl2 (1 :
2, 800mL) was added DMAP (1.5g, 12mmol), diiso-
propylethylamine (2.0mL, 12mmol), and DPPA (2.6mL,
12mmol), and the resulting mixture was stirred for 22h
at 90
◦C. To the reaction mixture was added H2O and the
organic layer was extracted with ethyl acetate. The extracts
were washed with brine, dried over MgSO4,ﬁ l t e r e d ,a n d
concentrated in vacuo. The residue was puriﬁed by column
chromatography on silica gel (ethyl acetate 100%) to give
10 as a white solid (1.7g, 1.9mmol 79%, mp = 220–225
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Figure 1: Structures of telomestatin and 6OTD dimers.
dec). Spectral data for 10:[ α]
25
D = −12 (c 0.4, CHCl3-
MeOH (1 : 1)); HH NMR (400 MHz, CDCl3) δ 8.54 (d, J
= 7.3Hz, 2H), 8.25–8.16 (m, 6H), 7.36–7.27 (m, 5H), 5.47–
5 . 3 7( m ,2 H ) ,5 . 0 5( b r ,2 H ) ,4 . 8 9( b r ,1 H ) ,4 . 5 9( b r ,1 H ) ,
3.22–2.98 (m, 4H), 2.30–1.89 (m, 4H), 1.62–1.18 (m, 17H);
13C NMR (100MHz, CDCl3) δ 164.8, 164.7, 161.2, 159.9,
159.8, 156.3, 156.0, 155.9, 154.6, 141.0, 140.9, 139.1, 138.4,
136.9, 136.8, 136.6, 130.9, 129.6, 128.4, 128.1, 128.0, 79.0,
66.5, 47.8, 47.7, 40.7, 40.3, 34.6, 29.5, 29.2, 28.4, 21.9, 21.8;
HRMS (ESI, M + Na) calcd for C43H44N10O12Na 915.3038,
found 915.2999.
Synthesis of 11. To a solution of macrocyclic bis-amide
10 (200mg, 220μmol) in MeOH (50mL) was added
Pd(OH)2/C (80mg) and the reaction mixture was stirred
at room temperature under hydrogen (balloon). After 5h,
the reaction mixture was ﬁltered through a pad of Celite,
and the ﬁltrates were concentrated in vacuo. To the residual
solution in DMF-MeCN (1:1, 4.0mL) was added diiso-
propylethylamine (190μL, 1.1 mmol) and adipoyl chloride
(16μL, 110μmol), and the mixture was stirred at room
temperature for 11h. The reaction mixture was concentrated
in vacuo, and the residue was acidiﬁed with 0.1 N HCl
and extracted with CHCl3. The organic layer was dried over
MgSO4,ﬁltrated,andconcentratedinvacuo.Theresiduewas
puriﬁed by column chromatography on silica gel (CHCl3–
AcOEt–MeOH = 3:2:1)togive11 (51mg, 31μmol, 28%).
Spectral data for 11:[ α]
25
D = −11 (c 0.95, CHCl3-MeOH
(1 : 1)); 1H NMR (500MHz, CDCl3) δ 8.67–8.48 (m, 4H),
8.27–8.15 (m, 12H), 6.38 (br, 2H), 5.47–5.38 (m, 4H), 4.84
(br, 2H), 3.30–2.98 (m, 8H), 2.15–1.90 (m, 12H), 1.65–
1.10 (m, 38H); 13C NMR (125MHz, CDCl3) δ 173.0, 164.9,
164.8, 159.8, 159.7, 156.2, 156.1, 156.0, 154.7, 154.6, 141.0,
140.9, 139.5, 139.3, 138.7, 138.6, 136.9, 136.8, 130.8, 129.5,
129.3, 78.9, 47.8, 47.7, 40.3, 38.9, 36.0, 34.5, 34.3, 29.7, 29.5,
28.8, 28.4, 25.1, 21.9, 21.7; HRMS (ESI, M + Na) calcd for
C76H82N20O22Na 1649.5810, found 1649.5811.
Synthesis of 2. As o l u t i o no f11 (50mg, 31μmol) in CH2Cl2-
TFA (95 : 5, 25mL) was stirred at room temperature for 2h.
The reaction mixture was concentrated in vacuo to give 2 as
a white solid (50mg, 30μmol, 98%, mp = 225–230
◦C dec).
Spectral data for 2:[ α]
25
D = 72 (c 0.3, CHCl3-MeOH (1:1));
1HNMR(500MHz,DMSOd−6)δ 9.15–9.08(m,8H),8.95–
8.89 (m, 4H), 8.38 (d, J = 6.9 Hz, 2H), 8.30 (d, J = 6.9Hz,
1H), 7.80–7.53 (m, 6H), 5.50–5.35 (m, 4H), 2.98–2.89 (m,
4H), 2.78–2.89 (m, 4H), 2.15–1.85 (m, 12H), 1.55–1.00 (m,
20H); 13C NMR (125 MHz, DMSO d − 6) δ 171.7, 164.5,
164.3, 158.8, 158.7, 155.6, 154.5, 142.5, 141.9, 141.8, 141.1,
136.0, 129.8, 129.7, 128.5, 128.4, 47.4, 47.3, 38.6, 38.1, 35.1,4 Journal of Nucleic Acids
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Scheme 1: Synthesis of 6OTD dimers. (a) Pd(OH)2/C, H2, THF-MeOH; (b) LiOH·H2O, THF-H2O; (c) DMT-MM, N-methylmorpholine,
THF-H2O, 89% over 2 steps from 4 and 6; (d) Pd(PPh3)4, morpholine, DMF-THF 99%; (e) LiOH·H2O, THF-H2O; (f) N,N-
diisopropylethylamine, DMAP, DPPA, DMF-CH2Cl2, 78% over 2 steps from 9;( g )P d ( O H ) 2/C, H2,M e O H ;h )N,N-diisopropylethylamine,
adipoylchloride,28%over2stepsfrom10;(i)TF A,CH 2Cl2 98%;(j)Et3N,HgCl2,1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea;
(k) TFA, CH2Cl2, 42%; Boc = tert-butoxycarbonyl, Cbz = benzyloxycarbonyl, DMT-MM = 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-
methylmorpholinium chloride, DMAP = 4-dimethylaminopyridine, DPPA = diphenylphosphoryl azide, TFA = triﬂuoroacetic acid.
33.1, 28.7, 26.7, 24.9, 21.3, 20.8; HRMS (ESI, M + H) calcd
for C66H67N20O18 1427.4942, found 1427.4961.
Synthesisof12. To a solution of 2(50mg,30μmol)inMeOH
(5.0mL) was added Amberlyst A-26(OH) ion-exchangeJournal of Nucleic Acids 5
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Figure 2: CD spectra of telo24 (10μΔM) in Tris-HCl buﬀer
(50mM, pH 7.0) with KCl (100mM) and/or ligands (50μM). (a)
solid line: telo24 + KCl; dashed line: telo24 + KCl + 2. (b) solid line:
telo24 + KCl; dashed line: telo24 + KCl + 3.
resin, and the mixture was stirred for 30minutes. The
resulting mixture was ﬁltered through a cotton with
MeOH, and the ﬁltrates were concentrated in vacuo. To
a residual solution of 2 in DMF (5.0mL) was added
diisopropylethylamine (52 μL, 0.31mmol), HgCl2 (50mg,
0.18mmol), and 1,3-Bis(tertbutoxycarbonyl)-2-methyl-2-
thiopseudourea (66mg, 0.18mmol), and the mixture was
stirred for 1h at room temperature. To the reaction mix-
ture was added H2O, and the organic layer was extracted
with ethyl acetate. The extracts were dried over MgSO4,
ﬁltered, and concentrated in vacuo. The residue was chro-
matographed on silica gel (CHCl3-ethyl acetate-MeOH =
3:2:1)togive12 as a white solid (30mg, 16μmol, 52%).
Spectral data for 12:[ α]
25
D = 3.8 (c 1.4, CHCl3-MeOH
(1:1)); 1H NMR (500MHz, CDCl3) δ 11.5 (br, 2H), 8.57–
8.48 (m, 4H), 8.30–8.17 (m, 14H), 6.17 (br, 2H), 5.45–5.36
(m, 4H), 3.41–3.32 (m 4H), 3.28–3.10 (m, 4H), 2.20–1.88
(m,12H),1.65–1.20(m,56H); 13CNMR(125MHz,CDCl3)
δ 172.9, 164.8, 164.7, 163.5, 159.9, 159.7, 156.1, 156.0, 154.7,
154.6, 153.2, 141.0, 140.9, 139.3, 139.2, 138.6, 138.5, 136.9,
136.8, 130.8, 129.6, 129.5, 82.9, 79.1, 47.7, 47.6, 40.5, 39.1,
36.0, 34.7, 28.7, 28.6, 28.2, 28.0, 25.0, 22.1, 22.0; HRMS
(ESI, M + Na) calcd for C88H102N24O26Na 1933.7295, found
1933.7332.
Synthesis of 3. As o l u t i o no f12 (29mg, 31μmol) in CH2Cl2-
TFA (3:1, 2.0 mL) was stirred at room temperature for 2h.
To the reaction mixture was added ether and precipitate was
formed. This precipitate was collected with ﬁltration using
ﬁlter paper, to give 3 as a white solid (20mg, 12μmol, 80%,
mp = 220–225
◦C dec). Spectral data for 3:[ α]
25
D = −18
(c 0.75, CHCl3-MeOH (1:1)); 1H NMR (400MHz, DMSO
d − 6) δ 9.14–9.08 (m, 8H), 8.94–8.90 (m, 4H), 8.37 (d, J
= 7.3Hz, 1H), 8.32 (d, J = 7.3Hz, 1H), 7.75–7.69 (m, 2H),
7.51–7.45 (m, 2H), 5.48–5.37 (m, 4H), 3.08–2.90 (m, 8H),
2.15–1.84 (m, 12H), 1.50–1.00 (m, 20H); 13C NMR (125
MHz, DMSO d−6) δ171.7, 164.5, 164.4, 158.8, 158.7, 156.7,
155.7, 155.6, 154.5, 142.5, 141.8, 141.1, 136.0, 129.8, 129.7,
128.5, 128.4, 47.4, 40.5, 38.1, 35.1, 33.4, 33.3, 28.7, 28.2,
24.9, 21.3, 21.0; HRMS (ESI, M+H) calcd for C68H71N24O18
1511.5378, found 1511.5368.
2.3. FRET Melting Assay. FRET melting assays were
performed as reported methods [34, 35] .T h ed u a lﬂ u o -
rescently labeled oligonucleotides Flu-telo21 5 -FAM-
[GGG(TTAGGG)3]-TAMRA-3  and Flu-ds26 5 -FAM-
[(TA)2GC(TA)2T6(TA)2GC(TA)2]-TAMRA-3  were used
in this protocol. The donor ﬂuorophore was 6-carboxy-
ﬂuorescein, FAM, and the acceptor ﬂuorophore was
6-carboxytetramethylrhodamine, TAMRA. The oligonucle-
otides were initially dissolved as a 100μMs t o c ks o l u t i o n
in MilliQ water; further dilutions were carried out in
60mM potassium cacodylate buﬀer (pH 7.4). Dual-labeled
DNA was annealed at a concentration of 400nM by
heating at 94
◦C for 5minutes followed by cooling to room
temperature. We added the diﬀerent concentrations of
ligands into diﬀerent samples, using a total reaction volume
of 40μL, with 200nM of labelled oligonucleotide. Then we
lay them at 25
◦C. Following experiments should keep the
temperature procedure in real-time PCR and procedure was
ﬁnished as following: 25
◦C for 5minutes, then a stepwise
increase of 1◦Ce v e r ym i n u t ef r o m2 5
◦Ct or e a c h9 9
◦C.
During the procedures, we measured the FAM after each
stepwise.
2.4. CD Spectroscopy. The 10μM oligonucleotide of telo24:
([TTAGGG]4) was dissolved in Tris-HCl buﬀer (50mM,
pH 7.0) and the solution was heated to 90
◦Cf o r5m i n u t e s ,
then slowly cooled to 25
◦C. G4 ligands were diluted from
10mM stock solutions to give a concentration of 1mM with
water and added into the oligonucleotide samples at 50μM
(the 10mM stock solutions of 2and 3 were made in DMSO).
2.5. ESI-MASS Spectrometry. ESI-MASS spectra were
recorded in a negative-ion mode with JEOL JMS-
T100X spectrometer. The direct-infusion ﬂow rate was
5.0μLm i n
−1. All experiments were performed in 20mM6 Journal of Nucleic Acids
0
40
80
120
160
200
I
n
t
e
n
s
i
t
y
1000 1200 1400 1600 1800 2000
(m/z)
[1 : 1]−5
[1 : 1]−6
[1 : 1]−7
Exact mass of ss-telo24 : 7571.27
Exact mass of 2 : 1426.47
[1 : 1]5− calcd for 1798.55 found 1799.64
[1 : 1]6− calcd for 1498.62 found 1499.59
[1 : 1]7− calcd for 1284.39 found 1285.21
(a)
0
40
80
120
160
200
I
n
t
e
n
s
i
t
y
1000 1200 1400 1600 1800 2000
(m/z)
[1 : 1]−5
[1 : 1]−6
[1 : 1]−7
Exact mass of ss-telo24 : 7571.27
Exact mass of 3 : 1510.53
[1 : 1]5− calcd for 1815.36 found 1816.56
[1 : 1]6− calcd for 1512.63 found 1513.71
[1 : 1]7− calcd for 1296.4 found 1297.38
(b)
Figure 3: ESI-MASS spectra of 10 μM telo24 with a 40 μM ligands 2 (a) and 3 (b).
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Figure 4: Plausible binding mode of the 6OTD dimers with telo24
[33].
NH4OAc containing 10μM of telo24 and 40μMo f2 and 3.
Methanol (15%) was added just before injection.
3. Results andDiscussion
3.1. Synthesis of 6OTD Dimers 2 and 3. The 6OTD dimers 2
and 3 were synthesized by using the sequences as shown in
Scheme 1.T r i o x a z o l e s4 and 6 were synthesized starting with
L-serine and L-lysine, respectively by using the previously
reported procedure [29, 30, 36–38]. The Cbz group of 4
was removed by treatment with hydrogen in the presence
of Pd(OH)2/C to give amine 5. Hydrolysis of the ester
group in 6 with lithium hydroxide followed by coupling of
the resulting acid with amine 5 using DMT-MM [39]g a v e
the bis-trioxazole amide 8. Cleavage of the allyloxycarbonyl
group in 8 and hydrolysis of the ester group produced an
amino acid, which was subjected to macrocyclization under
high dilution conditions (5mM) to give 6OTD 10. The Cbz
group in 10 was removed with hydrogen in the presence of
Pd(OH)2/C to give corresponding amine. The procedure for
synthesis of dimer 11 involved coupling of the amine with
adipoyl chloride. Bis-amine 2 was obtained by removal of
the Boc group of 11 with TFA. Preparation of the guanidine
derivative 3 was carried out by guanidination of the amine
moiety in 2 by using 1,3-bis(tert-butoxycarbonyl)-2-methyl-
2-thiopseudourea followed by deprotection of Boc group
with TFA.
3.2. Binding Properties of 2 and 3 toward Telomeric
G4. With the desired 6OTD dimers 2 and 3 in hand,
their mode of interaction with the telomeric DNA (telo24)
was investigated. Firstly, conformational changes of telo24,
induced by these substances were evaluated using circular
dichroism(CD)spectroscopy.Upontreatmentoftelo24with
6OTD dimers 2 and 3 (50μM) in the presence of potassium
chloride (100mM), the mixed-type structure induced by
potassium cation (solid line in Figure 2)i st r a n s f o r m e d
to a typical antiparallel-type G4 structure (dashed line in
Figure 2)[ 28, 40]1. The binding stoichiometries of the
complexes formed between the telo24 and ligands and 3
(molar ratio = 1:4) were determined by using ESI-MASS
spectrometric analysis [41, 42]. In both cases, only mass
peaks that correspond to 1:1 complexes of both 2 and 3
with telo24 were observed (at the 7-, 6- or in the 5-charge
states). Since these interaction modes are the same as that of
6OTD dimer 1, the newly synthesized 6OTD dimers 2 and 3Journal of Nucleic Acids 7
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Figure 5: ΔTm values of 0.2μM Flu-telo21 (a) and Flu-ds26 (b) in the presence of ligands 2 (solid line) and 3 (dashed line).
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appear to interact with telo24 through an end stacking mode
usingtwo6OTDmoieties in a manner similar to thatof TMS
and/or 6OTD dimer 1 (Figures 4 and 6)[ 33]
2,3.
The ability to stabilize the G4 structure of telo24 by
6OTD dimers 2 and 3 was evaluated by employing a
ﬂuorescence resonance energy transfer -(FRET-) based assay
[34, 35]. The ΔTm values of labeled oligonucleotide ﬂu-
telo21 with 2 and 3 at a concentration of 1μM, which
corresponds to 5 equivalents, are 10 and 14
◦C, respectively
(Figure 5(a) and Table 1). Since under the same conditions
theΔTm valuefor1was12
◦C,amongthesubstancesexplored
to date guanidine 3 is a potent stabilizer of the G4 structure4.
This stabilization eﬀect is likely caused by the attractive
interaction between positively charged guanidinium residue
and anionic phosphates backbone of the telomeric G4. Inter-
actions of the ligands with the duplex form of ﬂu-ds26 were
also investigated by using the same protocol (Figure 5(b)
and Table 1). The observation that no diﬀerences in the
ΔTm values exist in the presence or absence of dimers 2 and
suggests that these ligands are selective for the telomere DNA
sequence.
Table 1: ΔTm values by FRET melting assay.
G4 ligands 23
ΔTm at 1 μM G4 ligands (ΔTm/
◦C)
Flu-telo21 10 14
Flu-ds26 0 0
4. Conclusions
In summary, the eﬀorts described above have led to the
design and syntheses of 2 and 3, two novel macrocyclic
hexaoxazole dimeric derivatives of 6OTD that have amine
and guanidine groups in their respective side chains. These
compounds, together with 6OTD dimer acetate 1,w e r e
found to induce a change of the telomeric DNA sequence of
telo24intoanantiparallelstructurethroughtheformationof
1:1 complexes with the DNA. The guanidine functionalized
6OTD dimer 3 was determined to have the greatest ability
to stabilize the telomere DNA sequence. Also, both dimers
selectively bind to the telomeric DNA sequence and not
double-stranded DNA. Further studies, aimed at the struc-
turaldevelopmentof6OTDdimerswithdiﬀerentlinkers,are
currently underway.
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Endnotes
1. Telomeric antiparallel intramolecular G-quadruplexes
have characteristic CD spectra consisting of a positive
peak at 290 nm and a negative peak at 260nm [28, 40].
2. A similar conformational change was observed for
6OTD dimer 1 by using CD spectroscopic analysis
of a solution of 10μM of telo24 in the presence
of potassium chloride (100mM) and Tris-HCl buﬀer
(50mM,pH 7.0)asshownin Figure6(solidline:telo24
+ KCl, dashed line: telo24 + KCl + dimer 1).
3. The6OTDdimer1alsointeractswithtelo24byforming
1:1 complex based on ESI-MASS analysis [33].
4. Under the same measurement conditions, the ΔTm
values in the presence of 1μM 1 are 12
◦C (Flu-telo21)
and 0◦C (Flu-ds26), respectively.
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